Topic: checkpoint inhibitors
Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.
Roche touted another win Thursday for Tecentriq. But the way some analysts see things, it may actually be a win for Merck's Keytruda
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug picked up an FDA breakthrough designation in liver cancer.
Tally another win for Bristol-Myers Squibb’s immunotherapy combination, this time in rare colon cancers.
All eyes have been on the I-O battle over lung cancer. But with its latest data, breast cancer leader Roche is bringing the fight to its home turf.
So far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win.
The FDA has warned that drugs from Merck and Roche might be hurting some bladder cancer patients’ survival chances. Now, it’s narrowed their labels.
BMS' Opdivo is finally under FDA consideration as a therapy for previously untreated lung cancer.
Opdivo goes directly to the lucrative lung cancer market with its first nod in China, where nearly 800,000 new patients are diagnosed each year.